Equine Magnetic Therapy, Inc
1-800-731-8463
1-800-731-8463
>>Continued
Double Blind Study of the therapeutic effectiveness of permanently magnetized foils on secondary myotendofasciopathies at different selected locations
Dr. med. Thomas Laser
Head physician of the Orthopaedic Department:
Orthopaedic - Chirotherapy and Social Medicine Practitioner
KLINIC BAVARIA
8351 Schaufling
by: Dr. Jens Martin
8. Conclusions
1. With reference to the tested trial criteria the therapeutic effectiveness of the magnetized foils is unmistakably higher than the placebo effect of the non-magnetized foils applied to the control group.
2. The average effectiveness comparison index for the "positive" differentiation category (see above) of the test criteria was with 4.6, the highest when treating the cervical pain syndrome, followed with 4.1 of the magnetic foil therapy for periarthropathy humeroscapularis and finally, amounted to 2.5 for the treatment of the local lumbar pain syndrome.
3. A principal statement in favor of a better application capability of the magnetic foil therapy within indication groups II and III is not possible, as the sectional groups did not always contain the same number of patients. A number of further factors, not controlled in the test, influenced conclusions to this effect.
Summary of results of test sheets 1 to 100
Evaluation prior to decoding (100 patients)
Criterion A
Criterion A
Category
|
Number of Patients
|
Better
|
48
|
Same
|
43
|
Worse
|
9
|
Criterion B
Category
|
Number of Patients
|
Reduced
|
33
|
Same
|
63
|
Increased
|
4
|
Category
|
Number of Patients
|
Better
|
48
|
Same
|
43
|
Worse
|
9
|
Criterion C
Criterion D
Category
|
Number of Patients
|
Discontinuations
|
6
|
Reduced
|
16
|
Maintained
|
78
|
Criterion A
Criterion B
Evaluation after decoding Magnetized foils total (50 patients)
Criterion C
Criterion D
Category
|
Number of Patients
|
Percentage
|
Better
|
35
|
70%
|
Same
|
13
|
26%
|
Worse
|
2
|
4%
|
Category
|
Number of Patients
|
Percentage
|
Reduced
|
25
|
50%
|
Same
|
25
|
50%
|
Increased
|
0
|
0%
|
Category
|
Number of Patients
|
Percentage
|
Decreased
|
23
|
46%
|
Same
|
26
|
52%
|
Higher
|
1
|
2%
|
Category
|
Number of Patients
|
Percentage
|
Discontinuations
|
4
|
8%
|
Reduced
|
9
|
18%
|
Maintained
|
37
|
74%
|
Criterion A
Magnetic foils total (Placebo control group = 50 patients)
Criterion B
Category
|
Number of Patients
|
Percentage
|
Better
|
13
|
26%
|
Same
|
30
|
60%
|
Worse
|
7
|
14%
|
Category
|
Number of Patients
|
Percentage
|
Reduced
|
8
|
16%
|
Same
|
38
|
78%
|
Increased
|
4
|
8%
|
Category
|
Number of Patients
|
Percentage
|
Decreased
|
5
|
10%
|
Same
|
39
|
78%
|
Higher
|
6
|
12%
|
Category
|
Number of Patients
|
Percentage
|
Discontinuations
|
2
|
4%
|
Reduced
|
7
|
14%
|
Maintained
|
41
|
82%
|
Criterion C
Criterion D
1. Assessment of subjective pain sensation (crit. A)
Evaluation after decoding (50p./50p.)
Patients' statements to magnetized BIOflex® foils (p) and non-magnetized BIOflex® foils (n)
List of abbreviations
Abbreviation
|
Meaning
|
n
|
Number of patients treated with non magnetized foils
|
p
|
Number of patients treated with magnetized foils
|
g
|
Total number of patients
|
1.1.
|
Local lumbar pain syndrome
|
cerv
|
Cervical pain syndrome
|
PHS
|
Periarthropathy (periarthritis) humeroscapularis
|
Differentiation Category
|
Number Of Patients
|
Better
|
48
|
Same
|
43
|
Worse
|
9
|
p
|
1.1g
|
n
|
27
|
37
|
10
|
10
|
25
|
15
|
2
|
7
|
5
|
p
|
cerv.g
|
n
|
4
|
6
|
2
|
1
|
6
|
5
|
0
|
1
|
1
|
p
|
PHS g
|
n
|
4
|
5
|
1
|
2
|
12
|
10
|
0
|
1
|
1
|
2. Movement restriction (crit. B)
Differentiation Category
|
Number Of Patients
|
Reduced
|
33
|
Same
|
63
|
Increased
|
4
|
p
|
1.1g
|
n
|
20
|
24
|
4
|
19
|
43
|
24
|
0
|
2
|
2
|
p
|
Cerv.g
|
n
|
3
|
4
|
1
|
2
|
8
|
6
|
0
|
1
|
1
|
p
|
PHS g
|
n
|
2
|
5
|
66
|
4
|
12
|
6
|
0
|
1
|
1
|
3. Usage of pain killers (crit. C)
Differentiation Category
|
Number Of Patients
|
Decreased
|
28
|
Reduced
|
65
|
IMaintained
|
7
|
p
|
1.1g
|
n
|
17
|
20
|
3
|
21
|
45
|
24
|
1
|
4
|
3
|
p
|
Cerv.g
|
n
|
3
|
4
|
1
|
2
|
8
|
6
|
0
|
1
|
1
|
p
|
PHS g
|
n
|
3
|
4
|
1
|
3
|
8
|
9
|
0
|
2
|
1
|
4. Other necessary accompanying therapy (crit. D)
Differentiation Category
|
Number Of Patients
|
Discontinuations
|
6
|
Reduced
|
16
|
Worse
|
78
|
p
|
1.1g
|
n
|
2
|
4
|
2
|
7
|
9
|
2
|
30
|
56
|
26
|
p
|
Cerv.g
|
n
|
1
|
1
|
0
|
1
|
3
|
2
|
3
|
9
|
6
|
p
|
PHS g
|
n
|
1
|
1
|
0
|
1
|
4
|
3
|
4
|
13
|
9
|
Test period: 01.10.1991 to 01.04.1992 KLINIK BAVARIA SCHAUFLING, April 1992
signed: Superintendent of clinical test, Dr. med. Th. Laser,Physician authorized for test, Dr. med. J. Martin
Scientific Studies / Testiomnals / Links / Contact Us / Home
If you don't want to order online, Please use,
our
Fax Order Form for Horse Products
or
Fax Order Form for Human Products.